Albuminuria and cardiovascular risk

D H Rigo; P M Jiménez; M Orias

doi:10.1016/j.hipert.2023.03.003

Albuminuria and cardiovascular risk

Hipertens Riesgo Vasc. 2023 Jul-Sep;40(3):137-144. doi: 10.1016/j.hipert.2023.03.003. Epub 2023 Sep 23.

Authors

D H Rigo¹, P M Jiménez², M Orias³

Affiliations

¹ Nephrology Service, Sanatorio Allende, Córdoba, Argentina.
² Nephrology Service, Hospital Marcial Vicente Quiroga, San Juan, Argentina.
³ Yale University, Department Internal Medicine, Sanatorio Allende, Córdoba, Argentina. Electronic address: marcelo.orias@gmail.com.

PMID: 37748947
DOI: 10.1016/j.hipert.2023.03.003

Abstract

Cardiovascular risk (CVR) estimation is a fundamental tool for guiding therapy. Albuminuria indicates target organ damage in an accessible, economic and non-invasive manner. Improves high-risk patient identification, especially in chronic kidney disease (CKD) and diabetes mellitus (DM). In addition, anti-albuminuric treatments may improve CVR. This would position albuminuria as a guide and therapeutic objective. Although the capacity of albuminuria as an epidemiological CVR marker in specific populations (hypertension, CKD, DM) is accepted, its profile as a risk marker in the general population and as a therapeutic target is controversial. There is ambiguous evidence regarding its predictive capacity, added to the fact that treatments such as SLGT2 blockers reduce CVR events regardless of albuminuria presence or magnitude. This review analyzes the available evidence on albuminuria as a CVR marker, a treatment goal and therapeutic guide.

Keywords: Albuminuria; Cardiovascular risk; Chronic kidney disease; Enfermedad renal crónica; Proteinuria; Riesgo cardiovascular.

Publication types

Review